Published in Int J Clin Oncol on August 17, 2011
A case of metastatic leptomeningeal carcinomatosis from early gastric carcinoma. World J Surg Oncol (2012) 0.91
Leptomeningeal carcinomatosis from gastric cancer: single institute retrospective analysis of 9 cases. Ann Surg Treat Res (2014) 0.91
Leptomeningeal carcinomatosis of gastric cancer misdiagnosed as vestibular schwannoma. J Korean Neurosurg Soc (2014) 0.83
Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer (1982) 4.40
The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (1980) 2.64
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res (1999) 2.50
Leptomeningeal metastases from solid malignancy: a review. J Neurooncol (2005) 1.94
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology (2005) 1.91
Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer (2000) 1.71
Leptomeningeal carcinomatosis in gastric cancer. J Neurooncol (2004) 1.71
A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol (1987) 1.26
Leptomeningeal carcinomatosis originating from gastric cancer: report of eight cases and review of the literature. Am J Clin Oncol (2003) 1.25
Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract. Cancer (2005) 1.25
Gastric leptomeningeal carcinomatosis: multi-center retrospective analysis of 54 cases. World J Gastroenterol (2009) 1.24
DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol (2010) 1.21
Management of leptomeningeal malignancy. Expert Opin Pharmacother (2005) 1.17
Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol (2003) 1.12
Leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer (2009) 1.01
Neoplastic meningitis-related prognostic significance of the Karnofsky performance status. Arch Neurol (2009) 0.94
"Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. Blood (1978) 0.92
The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med (2005) 6.23
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol (2012) 4.19
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol (2013) 3.26
Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med (2015) 3.09
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol (2010) 2.73
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol (2003) 2.31
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep (2006) 1.91
Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc (2003) 1.82
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys (2010) 1.71
A new technique for endoscopic mucosal resection with an insulated-tip electrosurgical knife improves the completeness of resection of intramucosal gastric neoplasms. Gastrointest Endosc (2002) 1.70
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol (2010) 1.69
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer (2006) 1.60
A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol (2007) 1.59
Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer. Gastrointest Endosc (2002) 1.55
Matrix metalloproteinase-3 secretion from human colonic subepithelial myofibroblasts: role of interleukin-17. J Gastroenterol (2003) 1.55
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01). Jpn J Clin Oncol (2008) 1.55
Interleukin-17 augments tumor necrosis factor-alpha-induced granulocyte and granulocyte/macrophage colony-stimulating factor release from human colonic myofibroblasts. J Gastroenterol (2005) 1.54
Glutamate receptor antagonists and benzodiazepine inhibit the progression of granule cell dispersion in a mouse model of mesial temporal lobe epilepsy. Epilepsia (2005) 1.53
Butyrate blocks interferon-gamma-inducible protein-10 release in human intestinal subepithelial myofibroblasts. J Gastroenterol (2005) 1.49
S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol (2008) 1.44
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol (2007) 1.41
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI. J Vasc Interv Radiol (2012) 1.38
Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Cancer Sci (2014) 1.30
Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol (2005) 1.29
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer (2011) 1.27
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol (2004) 1.26
Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys (2003) 1.25
Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs (2010) 1.25
Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol (2010) 1.24
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci (2013) 1.20
EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc (2003) 1.19
Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan Clinical Oncology Group Study JCOG 0705 and Korea Gastric Cancer Association Study KGCA01. Jpn J Clin Oncol (2008) 1.19
Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer. Radiother Oncol (2010) 1.18
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer (2010) 1.18
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci (2011) 1.17
Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol (2012) 1.16
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol (2010) 1.16
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol (2013) 1.15
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2009) 1.13
Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol (2011) 1.12
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs (2012) 1.11
The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One (2011) 1.11
Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer (2011) 1.08
Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol (2010) 1.05
Regulation of IL-11 expression in intestinal myofibroblasts: role of c-Jun AP-1- and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol (2003) 1.04
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Invest New Drugs (2014) 1.03
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci (2010) 1.03
Present status and perspectives of colorectal cancer in Asia: Colorectal Cancer Working Group report in 30th Asia-Pacific Cancer Conference. Jpn J Clin Oncol (2010) 1.03
Metastatic skull tumors: MRI features and a new conventional classification. J Neurooncol (2010) 1.02
A phase II trial of endoscopic submucosal dissection for mucosal gastric cancer: Japan Clinical Oncology Group Study JCOG0607. Jpn J Clin Oncol (2009) 1.02
Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. Lung Cancer (2011) 1.02
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol (2011) 1.01
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs (2013) 1.01
Carcinoma of duodenum arising from Brunner's gland. J Gastroenterol (2002) 1.00
Radiotherapy for patients with symptomatic intramedullary spinal cord metastasis. J Radiat Res (2011) 1.00
Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. BMC Cancer (2013) 0.99
Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun (2011) 0.97
A phase II clinical trial of endoscopic submucosal dissection for early gastric cancer of undifferentiated type: Japan Clinical Oncology Group study JCOG1009/1010. Jpn J Clin Oncol (2012) 0.97
Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis. Biochem Biophys Res Commun (2008) 0.97
Endoscopic ultrasonography-guided fine needle aspiration biopsy using 22-gauge needle in diagnosis of autoimmune pancreatitis. Dig Liver Dis (2011) 0.97
Carcinoma coexisting with esophageal leiomyoma. Gastrointest Endosc (2002) 0.96
S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol (2010) 0.96
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.96
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan. Jpn J Clin Oncol (2012) 0.95
Usefulness of positron emission tomography in the evaluation of distribution and activity of systemic lesions associated with autoimmune pancreatitis. Pancreatology (2009) 0.95
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci (2014) 0.95
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer (2010) 0.95
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial. Jpn J Clin Oncol (2013) 0.94
KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol (2013) 0.94
Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. Int J Oncol (2006) 0.94